ORIGINAL ARTICLE. Two-Year Effects of Quality Improvement Programs on Medication Management for Depression
|
|
- Prosper Goodwin
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Two-Year Effects of Quality Improvement rograms on Medication Management for Depression Jürgen Unützer, MD, MH; Lisa Rubenstein, MD, MSH; Wayne J. Katon, MD; Lingqi Tang, hd; Naihua Duan, hd; Isabel T. Lagomasino, MD; Kenneth B. Wells, MD, MH Background: Significant underuse of evidence-based treatments for depression persists in primary care. We examined the effects of 2 primary care based quality improvement (QI) programs on medication management for depression. Methods: A total of 1356 patients with depressive symptoms (60% with depressive disorders and 40% with subthreshold depression) from 46 primary care practices in 6 nonacademic managed care organizations were enrolled in a randomized controlled trial of QI for depression. Clinics were randomized to usual care or to 1 of 2 QI programs that involved training of local experts who worked with patients regular primary care providers (physicians and nurse practitioners) to improve care for depression. In the QI-medications program, depression nurse specialists provided patient education and assessment and followed up patients taking antidepressants for up to 12 months. In the QI-therapy program, depression nurse specialists provided patient education, assessment, and referral to study-trained psychotherapists. Results: articipants enrolled in both QI programs had significantly higher rates of antidepressant use than those in the usual care group during the initial 6 months of the study (52% in the QI-medications group, 40% in the QItherapy group, and 33% in the usual care group). atients in the QI-medications group had higher rates of antidepressant use and a reduction in long-term use of minor tranquilizers for up to 2 years, compared with patients in the QI-therapy or usual care group. Conclusions: Quality improvement programs for depression in which mental health specialists collaborate with primary care providers can substantially increase rates of antidepressant treatment. Active follow-up by a depression nurse specialist in the QI-medications program was associated with longer-term increases in antidepressant use than in the QI model without such follow-up. Arch Gen sychiatry. 2001;58: From the Neuropsychiatric Institute, University of California, Los Angeles (Drs Unützer, Tang, Duan, and Wells); VA Greater Los Angeles Healthcare System (Dr Rubenstein) and the Department of sychiatry, Charles R. Drew University (Dr Lagomasino), Los Angeles, Calif; RAND, Santa Monica, Calif (Drs Rubenstein and Wells); and the Department of sychiatry, University of Washington, Seattle (Dr Katon). DERESSION is a major cause of disability worldwide 1 and is common in primary care. 2,3 Despite dissemination of practice guidelines for depression, 4-6 significant underuse of evidence-based treatments for depression persists in primary care. 7,8 Quality improvement (QI) efforts in primary care have been shown to increase rates of care and clinical outcomes for major depression for up to 8 months, 9-12 but improvements in care were not sustained at longer-term followups. 13,14 We describe the impact of 2 QI interventions on the use of antidepressant medications and minor tranquilizers over 2 years. This article is based on a randomized quasi experiment of an evidencebased QI intervention that was conducted in 46 nonacademic managed primary care practices in 5 states. Clinics were randomized to usual care (UC) or to 1 of 2 QI programs. 15,16 To mirror the diverse clinical status of patients in community primary care settings, the study included depressed patients who met the research diagnostic criteria for major depression or dysthymic disorder and those with subthreshold depression. 15 In this article, we follow the Institute of Medicine s formulation of quality of care 17 and examine whether problems with underuse (lack of use of maintenance antidepressants by patients at high risk for relapse) or overuse (inappropriate long-term use of minor tranquilizers for depression) were affected by our interventions. We expected that the QImedications (QI-Meds) program would lead to higher rates of antidepressant use than the QI-therapy program because of additional resources devoted to following up patients taking antidepressant medications. RESULTS TREATMENTS FOR DERESSION There were no significant baseline differences in the use of depression treatments (antidepressants or psychotherapy) by in- 935
2 ATIENTS AND METHODS STUDY DESIGN AND STUDY SITES artners in Care is a group-level randomized controlled trial carried out in 6 nonacademic managed care organizations in geographically diverse areas of the country. 15 Forty-six of 48 clinics belonging to these 6 organizations and 181 of 183 primary care providers (physicians and nurse practitioners) agreed to participate. Clinics were grouped into 27 clusters that were matched into 9 blocks of 3 clusters each based on patient demographics, clinician specialty, and distance to specialty mental health providers (psychiatrists, psychologists, or psychotherapists). Within each block, clinic clusters were randomly assigned to UC or to 1 of 2 QI programs (QI-Meds or QI-therapy). articipating organizations included prepaid, staff-model, mixed fee-for-service/prepaid, and networkmodel group practices and rural, managed, public health clinics. 16 Study staff screened consecutive patients in the waiting rooms of participating clinics during a 6-month period between June 1996 and March Eligible patients were aged 18 years or older, intended to use the clinic as their main source of medical care in the coming year, and were determined to have depression by a 6-item screening instrument that included the stem items for major depression and dysthymic disorder from the 12-month Composite International Diagnostic Interview (CIDI; edition 2.1), and items assessing the presence of depressive symptoms in the past month. Based on research diagnoses obtained by the full affective disorders section of the CIDI, the positive predictive value of this screener for depressive disorder (major depression or dysthymic disorder) was 55%. 15 atients who had an immediate medical emergency, did not speak English or Spanish, or did not have either insurance or a public-pay arrangement that covered the study interventions were excluded. A total of persons were approached in clinic waiting rooms, but were not eligible for screening, mainly because they were not patients of participating primary care providers. Of the patients completing the screener, 3918 were potentially eligible, but many left the clinic before completing the multistage enrollment process. Of the 2417 patients available to confirm insurance eligibility, 241 had ineligible health insurance. Of those who read the informed consent, 1356 enrolled. The remaining 21% either refused to participate or left the clinic. The enrolled sample includes 443 patients in the UC group, 424 in the QI-Meds group, and 489 in the QI-therapy group (Table 1). We controlled for differences in sex, educational level, and depression diagnosis in the analyses. INTERVENTIONS Our QI approach used a combination of expert intervention design, local managed care organization involvement, and provider behavior change strategies that have been described in detail previously. 16 Both QI interventions had a common core of physician education and patient screening, assessment, and education by a depression nurse specialist (DNS). hysician and nurse education followed a treatment manual adapted from the Agency for Healthcare Research and Quality (formerly the Agency for Health Care olicy and Research) treatment guidelines for depression in primary care. 18 roviders in both groups were encouraged to initiate treatment with antidepressants or psychotherapy for patients who met the diagnostic criteria for major depression or dysthymic disorder. atients and providers were free to use either antidepressant medications or psychotherapy, both, or neither. In addition to this common core, each intervention provided clinics with a unique set of resources. The QI-Meds program provided participants in clinics that had been randomized to this intervention access to a DNS who offered to support ongoing antidepressant treatment by the patients primary care providers for either 6 or 12 months (randomly assigned at the patient level). This follow-up focused on increasing adherence to guidelines for appropriate use of antidepressant medications. 18 In the QI-therapy program, DNSs assisted all patients in QI-therapy clinics whose clinicians determined that psychotherapy was appropriate, with a referral to a studytrained psychotherapist to offer individual or group cognitivebehavioral therapy at a reduced copayment. 16 rior analyses showed that the DNSs attempted to contact 96% of eligible patients with depression, and completed an initial assessment visit with 73% (76% in the QI-Meds group and 71% in the QI-therapy group). About 55% of eligible participants completed all visits with the DNS. The mean number of nurse follow-up contacts was 1.8 in the QI-therapy group and 5.1 in the QI-Meds group. 16 Usual care clinics were mailed copies of the Agency for Healthcare Research and Quality provider guidelines for depression in primary care. 4 atients in these clinics had access to all usually available primary care or specialty mental health treatments, but no extra resources were provided by the study. OUTCOMES EXAMINED Enrolled patients were asked to complete a telephone interview that included the affective disorders section of the CIDI, information on comorbid anxiety disorders, and economic information at baseline. atients also completed a self-administered mail survey at baseline and at 6, 12, 18, and 24 months. The surveys assessed the use of psychotherapy or prescription medications during the prior 6 months. We updated dosage recommendations from the tervention status (Table 3). At baseline, the rate of any treatment was somewhat higher in the QI-therapy group than in the UC group, and we controlled for this in our analyses. During the initial 6 months of the study, antidepressant use was greater in the QI-Meds and QI-therapy groups than in the UC group. atients in the QI-Meds group were more likely than patients in the UC group to report antidepressant use at 6, 12, 18, and 24 months, but the difference was only statistically significant at 6 and 12 months. atients in the QI-Meds group had significantly higher rates of antidepressant use than those in the QI-therapy group at 6, 12, and 24 months. articipants in the QI-Meds group who were randomly assigned to nurse case management for 12 months did not have higher rates of antidepressant use than those who 936
3 Agency for Healthcare Research and Quality treatment guidelines 4 for newer antidepressants using a consensus panel of 10 academic expert psychiatrists, and used the low end of the dosage recommendations as minimum recommended daily doses (Table 2). Because the study enrolled a clinically diverse group of patients with major depression, dysthymic disorder, and subthreshold depression for whom treatment guidelines are less clear, we used 2 approaches to examine care for depression. For the entire sample of patients (including those with subthreshold depression), we describe any use of antidepressant medications (either 1 month of use during the prior 6 months or any use in the prior 30 days) or any counseling (at least 1 visit) as indicators of depression treatment. For the 562 subjects who met the diagnostic criteria for DSM-IV major depression or dysthymic disorder at baseline and who were at high risk of relapse based on dysthymic disorder or a history of 2 or more episodes of depression, we examined 3 additional quality indicators: antidepressant use at minimum daily recommended doses (Table 2) for at least 25 of the past 30 days, for at least 2 of the past 6 months, and for at least 6 months in the past year (data for this indicator are not available at 24 months). We also examined long-term minor tranquilizer use (use for 3 of the past 6 months). Our intervention materials recommended against such long-term use in patients with depression who did not have comorbid anxiety disorders because of the lack of efficacy data for this group of patients and because of substantial costs and risks associated with the long-term use of minor tranquilizers. STATISTICAL ANALYSES Our analyses examine the effects of the 2 QI models (randomly assigned at the clinic level) compared with UC on the use of medications by patients enrolled in the respective clinics. We used all 1092 subjects who had baseline data and at least one follow-up data point and who did not meet the CIDI criteria for bipolar disorder for the analyses. We performed multilevel analyses, testing the primary hypotheses that the intervention conditions increased rates of treatment (as previously specified) significantly more than UC. We tested secondary hypotheses about the targeting of depression treatments by performing analyses that interacted the intervention status with baseline disorder status, treatment preferences, and prior treatment. Because both interventions recommended against the long-term use of minor tranquilizers in patients without comorbid anxiety disorders, we also tested the hypothesis that patients in the QI clinics had lower rates of potentially inappropriate minor tranquilizer use over time. For each dependent variable, we fitted 3-level mixedeffects logistic regression models using follow-up data at 6, 12, 18, and 24 months with regression adjustment for baseline depression treatments in the past 6 months, accounting for the multilevel data structure with patients nested within clinics and repeated measurements nested within patients. We treated time as a categorical variable, and examined the fixed effects for time, intervention condition, and their interactions. To account for the intraclass correlation expected in the data, we specified random effects at the clinic and patient level, including random intercepts and random slopes for the difference among waves. At the patient level, we specified the covariance structure among the random effects as the most general unstructured model. At the clinic level, we specified a more restrictive variance component model because of the limited degrees of freedom available. Our model specification is analogous to the models used by others We also included several covariates for additional adjustment: age, squared age, sex, educational level (less than high school, completed high school, some college, completed college, or more), chronic medical conditions from a total of 19 (0, 1, 2, or 3), depressive disorder determined by the CIDI, an indicator of having at least 2 prior depressive episodes, comorbid anxiety disorders (CIDI), likely problem drinking determined by the Alcohol Use Disorders Identification Test, baseline preferences for treatment (antidepressant medications, counseling, nothing, or wait), study site, and a summary variable of household wealth modeled after the Health and Retirement Survey. To test intervention effects at each time point (months 6, 12, 18, and 24), we conducted pairwise 2-sided t tests comparing QI-Meds vs UC, QI-therapy vs UC, and QI- Meds vs QI-therapy. To present the effect size of intervention effects, we calculated standardized predictions for each outcome studied. 22 In deriving these predictions, regression parameters and each individual s actual covariate values other than intervention status are used to derive 3 predicted values for each individual, first as a QI-Meds group subject, then as a QItherapy group subject, and then as a UC group subject. redictions under the QI-Meds scenario are then averaged across the entire analytic sample to obtain an overall assessment of the QI-Meds outcome; the procedure is then repeated for the other conditions. This procedure thus standardizes the comparisons to the characteristics of the full analytic sample. We used an extended hot deck multiple imputation technique that modifies the predictive mean matching method 23 to impute missing covariates. (Outcome variables were not imputed.) Instead of filling in a single value for each missing value, we used the multiple imputation strategy of Rubin 24 to create 5 imputed data sets. Each of 5 complete data sets was then analyzed using standard complete-data methods. The predictions across 5 imputed data sets were combined by averaging, and SEs were derived using the Rubin method to combine within-imputation variability and between-imputation variability. were assigned to case management for 6 months (data not shown). As a context for our findings on antidepressant use, we also examined rates of any depression treatment (any use of antidepressants or psychotherapy) in the prior 6 months. At 6 months, patients in the QI-Meds and QItherapy groups reported higher rates of any depression treatment than those in the UC group. Those in the QI- Meds group had consistently higher rates of any depression treatment than those in the UC or QI-therapy group, but the difference was only statistically significant at 6 and 12 months. Further detail on counseling treatments is available elsewhere. 16,17 We observed significant interaction effects of intervention type with disorder status (F=4.09, =.02) and intervention type with prior use of counseling (F=7.49, 937
4 Table 1. Characteristics of the 1356 Subjects: Overall and by Intervention Conditions* Sample Characteristics All (N = 1356) (n = 424) QI rogram Therapy (n = 489) Usual Care (n = 443) Group Test Age, mean (SD), y 43.0 (14.3) 43.1 (13.7) 43.6 (15.5) 42.4 (13.5).41 Female sex Ethnicity Hispanic African American Other minority White Education High school High school Some college College Net Worth in $1000, mean (SD) (385.8) (243.1) 98.6 (177.6) (603.6) mo Depressive disorder Depression diagnosis (from CIDI) Double depression Major depression Dysthymia only Depressive symptoms.001 With lifetime major depression Without lifetime major depression History of 2 lifetime episodes of major depression Thoughts of suicide in the past 12 mo Lifetime history of mania (from CIDI) Comorbid anxiety disorder No. of chronic medical illness Likely problem drinking *Data are given as the percentage of subjects unless otherwise indicated. ercentages may not total 100 because of rounding. QI indicates quality improvement; CIDI, Composite International Diagnostic Interview. The F test was used to compare differences across intervention conditions. The SD is given for continuous variables only..001), indicating greater targeting of antidepressants to patients with depressive disorders or those who underwent prior counseling in the 2 intervention groups than in the UC group. For example, at the 6-month followup, between 26% (UC group) and 38% (QI-Meds group) of the participants who did not meet the CIDI criteria for major depression or dysthymic disorder at baseline reported using antidepressants, compared with 37% (UC group) to 62% (QI-Meds group) of those who had depressive disorders at baseline. The Figure shows standardized predictions of the proportion of patients who used antidepressants during the 2-year study period stratified by baseline antidepressant use. These estimates were derived from the mixed-effects logistic regression model that included interactions of intervention type with prior treatment and disorder status. TYES OF ANTIDERESSANTS USED At baseline, selective serotonin reuptake inhibitors accounted for about 60% of the antidepressants used in all 3 groups; other newer antidepressants, such as bupropion hydrochloride, nefazodone hydrochloride, or venlafaxine hydrochloride, accounted for about 20%; tertiary amine tricyclic antidepressants accounted for about 15%; and secondary amine tricyclic antidepressants accounted for about 5%. Monoamine oxidase inhibitors and other antidepressants, such as amoxapine or maprotiline, represented less than 1% of all antidepressants used. During the 2 years of follow-up, there was a slight increase in the use of newer antidepressants other than selective serotonin reuptake inhibitors in all 3 groups and a corresponding decrease in the use of tricyclic antidepressants. Between 5% and 9% of the participants used more than 1 antidepressant during each 6-month period. There were no substantial intervention group differences in the types of antidepressants used over time. ADEQUACY OF ANTIDERESSANT USE AMONG SUBJECTS WITH DERESSION AT HIGH RISK FOR RELASE Most patients (562 of 674) who met the criteria for major depression or dysthymic disorder at baseline were at high risk for relapse, as defined by current dysthymic disorder or a history of 2 or more episodes of depression
5 At baseline, patients in the QI-therapy group at high risk for relapse reported significantly greater antidepressant use than patients in the QI-Meds or UC group (Table 4), and we controlled for these baseline differences in the analyses. Table 2. Guideline-Level Antidepressant Doses for atients With Depressive Disorders Minimum Recommended Type of Antidepressant* Dose, mg/d Newer antidepressants SSRIs Fluoxetine hydrochloride 10 Fluvoxamine maleate 100 aroxetine 20 Sertraline hydrochloride 50 Citalopram hydrochloride 20 Not SSRIs Bupropion hydrochloride 200 Mirtazapine 15 Nefazodone hydrochloride 200 Trazodone hydrochloride 150 Venlafaxine hydrochloride 75 Tricyclic antidepressants Secondary amines Desipramine hydrochloride 75 Nortriptyline hydrochloride 40 rotriptyline hydrochloride 20 Tertiary amines Amitriptyline hydrochloride 75 Clomipramine hydrochloride 75 Doxepin hydrochloride 75 Imipramine hydrochloride 75 Trimipramine maleate 75 Other heterocyclic antidepressants Amoxapine 100 Maprotiline hydrochloride 100 Monoamine oxidase inhibitors henelzine sulfate 45 Tranylcypromine sulfate 20 *SSRI indicates selective serotonin reuptake inhibitor. Rates of guideline-level antidepressant use, as defined by our 3 quality indicators, were significantly greater in the QI-Meds group than in the UC group at 6, 12, and 18 months but not at 24 months. Appropriate antidepressant use was consistently higher in the QI-Meds group than in the QI-therapy group, but the differences were not always statistically significant. LONG-TERM USE OF MINOR TRANQUILIZERS The proportion of subjects using minor tranquilizers for more than 3 months at baseline ranged from 7.1% (QItherapy group) to 9.2% (UC group). At the 24-month follow-up, 6.2% of the patients in the QI-Meds group reported long-term use of minor tranquilizers compared with 10.0% in the QI-therapy group (t= 2.01, =.04) and 10.3% in the UC group (t= 1.87, =.06). A similar picture emerged when we examined the use of minor tranquilizers for 3 or more months without a concurrent prescription of an antidepressant medication. Over 2 years, this rate declined from 4.6% to 2.5% in the QI-Meds group, but it remained relatively stable in the QI-therapy (4%- 6%) and the UC (4%-7%) groups. There was no significant interaction between anxiety disorder status and intervention group, meaning that the interventions did not increase the targeting of longterm minor tranquilizers to those who had comorbid anxiety disorders. COMMENT Our results suggest that QI interventions that combine key components from established chronic care models, 25,26 such as clinician education, patient education, case management, and specialist involvement in primary care, can lead to relatively long-term increases in antidepressant use in managed primary care practices. rior studies 27,28 document that less intensive interventions, such as provider feedback, do not lead to persistent increases Table 3. Use of Depression Treatments by 1092 Depressed articipants* QI rogram vs UC Therapy vs UC vs Therapy Time, mo (n = 349) Therapy UC (n = 388) (n = 355) t Test Any Antidepressant Use in the ast 6 mo Baseline Any Depression Treatment (Antidepressant Use or sychotherapy) in the ast 6 mo Baseline *Analyses included all 1092 depressed participants with a baseline and at least 1 follow-up data point and who did not meet composite International Diagnostic Interview criteria for bipolar disorder. They are adjusted for baseline treatment status and covariates. The baseline analysis also includes a dummy variable specifying more than a 30-day delay between enrollment and completion of the baseline survey. QI indicates quality improvement; UC, usual care. Data are given as the percentage of participants. t Test t Test 939
6 in depression treatment or improvement in clinical outcomes. The necessity for a more intensive model of care for changing antidepressant use is consistent with the literature on health care provider behavior in general, which indicates that while 1-step behaviors such as ordering a mammogram have responded to computer feedback, conditions requiring sustained patient and provider behavior change have not. While short-term antidepressant use was increased by the QI-Meds and QI-therapy interventions, longer-term increases in the rates of medication use were limited to the QI-Meds group. The increased antidepressant use in the QI-therapy and QI-Meds groups at 6 months implies that intervention components common to the 2 interventions Standardized redictions of % of Subjects Using Antidepressants QI- Group QI-Therapy Group Usual Care Group Antidepressant Used at Baseline (n = 405) Antidepressant Not Used at Baseline (n = 687) Survey Wave, mo roportion of patients who used antidepressants in the prior 6 months stratified by baseline antidepressant use. QI indicates quality improvement. improved antidepressant use in the short-term. These include provider education, collaboration of primary care providers with DNSs, assessment and education of patients by the DNS, and encouragement of the use of antidepressant medications or psychotherapy for patients with major depression or dysthymic disorder. The finding of greater antidepressant use in the QI-Meds group at 12, 18, and 24 months implies that the addition of at least 6 months of active follow-up by a DNS (available in QI-Meds practices only) is associated with relatively long-term increases in the use of antidepressants. Contrary to our expectations, patients in the QI-Meds group who were in the 12-month case management group had no greater use of antidepressants than those who were in the 6-month case management group over time. This could be because 12-month case management has no additional effect compared with 6 months or because most patients eligible for the 12- month follow-up did not use it for the full available duration. 16 Future studies should examine if even shorter periods of follow-up (ie, 3 months) can achieve similar effects on antidepressant use or if a more fully implemented longerterm follow-up would lead to even greater long-term increases in medication use. Earlier trials 9-11 of collaborative care for depression included patients who had already started taking antidepressants. We found that patients with and without prior antidepressant treatment had increases in their rates of care, suggesting that QI interventions for depression are effective in increasing antidepressant use in both groups. While treatment rates were between 50% and 75% higher in the QI groups than in the UC group, it is important to emphasize that only about 50% of patients who met the diagnostic criteria for major depression or Table 4. Antidepressant Use by the 562 articipants With Depression at High Risk for Relapse* QI rogram vs UC Therapy vs UC vs Therapy Time, mo (n = 197) Therapy UC (n = 213) (n = 152) t Test Antidepressant Use at the Guideline-Level Dose for at Least 25 of the ast 30 d Baseline Antidepressant Use at the Guideline-Level Dose for at Least 2 of the ast 6 mo Baseline Antidepressant Use at the Guideline-Level Dose for at Least 6 mo in the ast Year Baseline *Subjects had major depression and at least 2 prior episodes of major depression or dysthymia. Analyses are adjusted for baseline treatment status and covariates. The baseline analysis also includes a dummy variable specifying more than a 30-day delay between enrollment and completion of the baseline survey. QI indicates quality improvement; UC, usual care. Data are given as the percentage of participants. Data are not available at 24 months. t Test t Test 940
7 dysthymic disorder at baseline received appropriate antidepressant management during the first 6 months of the study. There is, thus, substantial room for improvement. Our interventions were less intensive than most previous evaluations of collaborative care for depression and were self-applied by usual nonacademic primary care practices to a diverse population of patients, without direct involvement of researchers in patient care. We expect that interventions to improve care for depression will show smaller effects in actual use than in carefully controlled trials because of the greater diversity of patients and primary care providers involved. The observed improvement in this study may mirror more closely than previous studies the impacts that might be achievable in a broad-scale dissemination of QI for depression. If these results held true in large-scale use, the health impact of such QI on a population level could be substantial. Our sample included several patients who did not meet the diagnostic criteria for depressive disorders, and the literature does not consistently support the efficacy of antidepressants or psychotherapy for subthreshold depression. Our educational materials encouraged clinicians to recognize subthreshold depression and to target antidepressant medications and full doses of cognitive-behavioral therapy to those with major depression or dysthymic disorder. atients with depression who were at risk for relapse had the highest rates of antidepressant use in all 3 groups, and patients at risk for relapse in the QI-Meds group had consistently higher rates of medication use than patients in the QI-therapy or UC group. Our study was not designed to determine the need for or effectiveness of long-term antidepressant use for different types of patients. Future studies should, thus, focus increased attention on the need for long-term follow-up and maintenance therapy for diverse populations of patients with depression. Our educational materials specifically recommended the use of secondary amine tricyclic antidepressants or selective serotonin reuptake inhibitors as first-line antidepressant medications and pointed out that both types of medications are equally efficacious. Despite this recommendation, secondary amine tricyclic agents accounted for 5% or less of the antidepressants used, and their use declined during the 2 years of the study. Selective serotonin reuptake inhibitors and other newer antidepressants made up about 80% of all antidepressants used, without substantial differences among intervention groups. The greater use of newer antidepressants that can be easier to titrate and tolerate than older antidepressants represents a substantial change from earlier studies 7,32,34 of depression management in primary care. The availability of newer antidepressants that are better tolerated and indicated for depression and anxiety disorders may also account for relatively low rates of longterm minor tranquilizer use compared with earlier studies. 7 Minor tranquilizer use was particularly low in participants without comorbid anxiety disorders, indicating that primary care providers targeted these medications to patients who were more likely to benefit from them. We discouraged the long-term use of minor tranquilizers in our educational materials, and we found substantial reductions in minor tranquilizer use in the QI- Meds group compared with the QI-therapy or UC group. Thus, it appears possible for QI interventions to simultaneously correct problems related to potential underuse of appropriate antidepressant medications and overuse of inappropriate long-term minor tranquilizers. While we sampled patients from 6 diverse organizations across the country, 15 our sample has limited generalizability to primary care in general. Our ability to generalize is further limited by a relatively high nonparticipation rate. We are also limited by our reliance on selfreport data for use of medications and counseling. It is possible that patients underreport such treatments, but an earlier study by Katon and colleagues 9 showed that self-report of antidepressant use during the past 30 days (one of our quality indicators) was strongly associated with automated pharmacy data. Our models may somewhat understate the true intervention effects because, over time, the need for treatment may have decreased more in the intervention groups than in the UC group. 15 An alternative method to examine the long-term effects of QI on antidepressant prescribing would have been to examine antidepressant use in a new cohort of patients with depression. It is also possible that more patients in the QI-therapy group had sustained clinical benefits that made it less necessary for them to undergo long-term antidepressant treatment. However, almost half of our participants were at high risk for relapse and, thus, candidates for long-term maintenance antidepressant treatment. 18 In conclusion, implementation of QI for depression by diverse managed primary care practices can substantially increase rates of antidepressant treatment for depression. The inclusion of at least 6 months of active nurse care management leads to larger and longer-term increases in antidepressant use than does the collaborative care model without such follow-up. Accepted for publication April 19, This study was supported by grant R01-HS08349 from the Agency for Healthcare Research and Quality, Rockville, Md; grant 50 MH54623 from the National Institute of Mental Health, Rockville; and grant A-HE from the John D. and Catherine T. MacArthur Foundation, Chicago, Ill. We thank Robert Bell, hd, Tom Belin, hd, and Daniel McCaffrey, hd, for their statistical advice; Maga Jackson- Triche, MD, MSHS, for her assistance with the design and implementation of the interventions; and Bernadette Benjamin, MS, for her meticulous programming support. This study is a sister study to the National Institute of Mental Health Cooperative Agreement to Test Depression ractice Guidelines (Lisa Rubenstein, MD, MSHS, Kathryn Rost, hd, and Daniel Ford, MD, MH, principal investigators). We acknowledge the following participating managed care organizations that provided access to their expertise and patients, implemented interventions, and provided in-kind resources: Allina Medical Group, Minneapolis, Minn; atuxent Medical Group, Columbia, Md; Humana Health Care lans, San Antonio, Tex; Medartners, Los Angeles, Calif; acificare of Texas, San Antonio; and Valley-Wide Health Services, San Luis Valley, Colo. We also acknowledge their in- 941
8 ternal behavioral health organizations and participating contract behavioral health organizations: Alamo Mental Health Group, San Antonio; San Luis Valley Mental Health/ Colorado Health Networks, San Luis Valley; and Greenspring Mental Health Services, Columbia. Finally, we acknowledge the clinicians and patients who contributed their time and efforts to this study. Corresponding author and reprints: Jürgen Unützer, MD, MH, Center for Health Services Research, Neuropsychiatric Institute, University of California, Los Angeles, Wilshire Blvd, Suite 300, Los Angeles, CA ( REFERENCES 1. Murray CJ, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Disease, Injuries, and Risk Factors in 1990 and rojected to Boston, Mass: Harvard School of ublic Health, on behalf of the World Health Organization and the World Bank; Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp sychiatry. 1992;14: Spitzer RL, Williams JB, Kroenke K, Linzer M, degruy FV III, Hahn SR, Brody D, Johnson JG. Utility of a new procedure for diagnosing mental disorders in primary care: the RIME MD 1000 study. JAMA. 1994;272: Depression Guidelines anel. Depression in rimary Care: Treatment of Major Depression. Rockville, Md: US Dept of Health and Human Services; AHRQ (formerly AHCR), US ublic Health Services, publication Schulberg HC, Katon WJ, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of the Agency for Health Care olicy and Research ractice Guidelines. Arch Gen sychiatry. 1998;55: Schulberg HC, Katon WJ, Simon GE, Rush AJ. Best clinical practice: guidelines for managing major depression in primary medical care. J Clin sychiatry. 1999; 60(suppl 7):19-26; discussion, Wells KB, Katon W, Rogers B, Camp. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the Medical Outcomes Study. Am J sychiatry. 1994;151: Wells KB, Schoenbaum M, Unützer J, Lagomasino I, Rubenstein L. Quality of care for primary care patients with depression in managed care. Arch Fam Med. 1999;8: Katon W, Von Korff M, Lin E, Walker E, Simon G, Bush T, Robinson, Russo J. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA. 1995;273: Katon W, Robinson, Von Korff M, Lin E, Bush T, Ludman E, Simon G, Walker E. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen sychiatry. 1996;53: Katon W, Von Korff M, Lin E, Simon G, Walker E, Unützer J, Bush T, Russo J, Ludman E. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen sychiatry. 1999;56: Schulberg HC, Block MR, Madonia MJ, Scott C, Rodriguez E, Imber SD, erel T, Lave J, Houck R, Coulehan JL. Treating major depression in primary care practice: eight-month clinical outcomes. Arch Gen sychiatry. 1996;53: Lin EH, Katon WJ, Simon GE, Von Korff M, Bush TM, Rutter CM, Saunders KW, Walker EA. Achieving guidelines for the treatment of depression in primary care: is physician education enough? Med Care. 1997;35: Lin E, Simon GE, Katon WJ, Russo JE, Von Korff M, Bush TM, Ludman EJ, Walker E. Can enhanced acute phase treatment of depression improve long-term outcomes? a report of randomized trials in primary care. Am J sychiatry. 1999; 156: Wells KB, Sherbourne C, Schoenbaum M, Duan N, Meredith L, Unützer J. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA. 2000;283: Rubenstein LV, Jackson-Triche M, Unützer J, Miranda J, Minnium K, earson ML, Wells KB. Evidence-based care for depression in managed primary care practices. Health Aff (Millwood). 1999;18: Chassin MR, Galvin RW. The urgent need to improve health care quality: Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280: Rubenstein LV, Unützer J, Miranda J, Katon W, Wieland M, Jackson-Triche M, Minnium K, Mulrow C, Wells K. Clinician Guide to Depression and Management in rimary Care Settings. Santa Monica, Calif: RAND; Gibbons RD, Bock RD. Trend in correlated proportions. sychometrika. 1987; 52: Gibbons RD, Hedeker D. Application of random-effects probit regression models. J Consult Clin sychol. 1994;62: Hedeker D, Gibbons RD. A random-effects ordinal regression model for multilevel analysis. Biometrics. 1994;50: Graubard BI, Korn EL. redictive margins with survey data. Biometrics. 1999; 55: Little RJ. Missing-data adjustments in large surveys. J Business Econ Stat. 1988; 6: Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons Inc; Wagner EH, Austin BT, Von Korff M. Improving outcomes in chronic illness. Manag Care Q. 1996;4: Katon W, Von Korff M, Lin E, Unützer J, Simon G, Walker E, Ludman E, Bush T. opulation-based care for depression: effective disease management strategies to decrease prevalence. Gen Hosp sychiatry. 1997;19: Simon GE, Von Korff M, Rutter C, Wagner E. Randomized trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ. 2000;320: Kroenke K, Taylor-Vaisey A, Dietrich AJ, Oxman TE. Intervention to improve provider diagnosis and treatment of mental disorders in primary care. sychosomatics. 2000;41: Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA. 1995;274: Rubenstein LV, Mittman BS, Yano EM, Mulrow CD. From understanding health care provider behavior to improving health care: the QUERI framework for quality improvement: Quality Enhancement Research Initiative. Med Care. 2000;38 (suppl 1):I129-I Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ. 1995; 153: Simon GE, Von Korff M, Wagner EH, Barlow W. atterns of antidepressant use in community practice. Gen Hosp sychiatry. 1993;15: Simon GE, Heiligenstein J, Revicki D, Von Korff M, Katon WJ, Ludman E, Grothaus L, Wagner E. Long-term outcomes of initial antidepressant drug choice in a real world randomized trial. Arch Fam Med. 1999;8: Katon W, Von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30:
Phase 2 Measures of Depression Population
Phase 2 Measures of Depression Population Each Phase 2 depression team is required to track and report the core national measures (measures 1 through 4) along with the count of patients with depression
More informationDepressive illness has been shown to be associated with
Effect on Disability Outcomes of a Depression Relapse Prevention Program MICHAEL VON KORFF, SCD, WAYNE KATON MD, CAROLYN RUTTER, PHD, EVETTE LUDMAN, PHD, GREG SIMON, MD, MPH, ELIZABETH LIN, MD, MPH, AND
More informationA COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY
A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,
More informationQUALITY OF CARE FOR DEPRESsion
ORIGINAL CONTRIBUTION Impact of Disseminating Quality Improvement Programs for Depression in Managed Primary Care A Randomized Controlled Trial Kenneth B. Wells, MD, MPH Cathy Sherbourne, PhD Michael Schoenbaum,
More informationORIGINAL ARTICLE. A Randomized Trial of Relapse Prevention of Depression in Primary Care
ORIGINAL ARTICLE A Randomized Trial of Relapse Prevention of Depression in Primary Care Wayne Katon, MD; Carolyn Rutter, PhD; Evette J. Ludman, PhD; Michael Von Korff, ScD; Elizabeth Lin, MD, MPH; Greg
More informationMaking an IMPACT on late-life depression. Partnering with primary care providers can double the effect of treatment
University of Massachusetts Boston From the SelectedWorks of Steven D Vannoy Fall September, 2006 Making an IMPACT on late-life depression. Partnering with primary care providers can double the effect
More informationLong-Term Effects on Medical Costs of Improving Depression Outcomes in Patients With Depression and Diabetes
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Long-Term Effects on Medical Costs of Improving Depression Outcomes in Patients With Depression and Diabetes WAYNE J. KATON, MD 1 JOAN
More informationIMPACT Improving Mood Promoting Access to Collaborative Treatment
IMPACT Improving Mood Promoting Access to Collaborative Treatment for Late-Life Depression Funded by John A. Hartford Foundation, California HealthCare Foundation, Robert Wood Johnson Foundation, Hogg
More informationTreating Depression in Disadvantaged Women: What is the evidence?
Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationDepressive disorders are common in primary care,
Do Clinician and Patient Adherence Predict Outcome in a Depression Disease Management Program? Catherine J. Datto, MD, Richard Thompson, PhD, David Horowitz, MD, Maureen Disbot, RN, Hillary Bogner, MD,
More informationDisability from depression: The public health challenge to primary care
Disability from depression: The public health challenge to primary care KATHRYN ROST Rost K. Disability from depression: The public health challenge to primary care. Nord J Psychiatry 2009;63:1721. Oslo.
More informationDEPRESSION Eve A. Kerr, M.D., M.P.H.
- 111-8. DEPRESSION Eve A. Kerr, M.D., M.P.H. We relied on the following sources to construct quality indicators for depression in adult women: the AHCPR Clinical Practice in Primary Care (Volumes 1 and
More information8. DEPRESSION 1. Eve A. Kerr, M.D., M.P.H. and Kenneth A. Clark, M.D., M.P.H.
8. DEPRESSION 1 Eve A. Kerr, M.D., M.P.H. and Kenneth A. Clark, M.D., M.P.H. We relied on the following sources to construct quality indicators for depression: the AHCPR Clinical Practice Guideline in
More informationDisparities in care for depression in the United States. Disparities in Care for Depression Among Primary Care Patients
Blackwell ORIGINAL Miranda and Publishing, Cooper, ARTICLE Ltd. in Care for Depression Disparities in Care for Depression Among Primary Care Patients Jeanne Miranda, PhD, Lisa A. Cooper, MD, MPH CONTEXT:
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationDepression & Diabetes: Pathways and TeamCare Studies
Depression & Diabetes: Pathways and TeamCare Studies Wayne Katon, MD 1 Mike VonKorff, ScD 2 Elizabeth Lin, MD, MPH 2 Paul Ciechanowski, MD, MPH 1 Evette Ludman, PhD 2 Joan Russo, PhD 1 Carolyn Rutter,
More informationDEPRESSION 1 Eve Kerr, M.D., M.P.H.
- 141-7. DEPRESSION 1 Eve Kerr, M.D., M.P.H. We relied on the following sources to construct quality indicators for depression in adult women: the AHCPR Clinical Practice in Primary Care (Volumes 1 and
More informationPartners in Care Quick Reference Cards
Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationThe Association Between Rural Residence and the Use, Type, and Quality of Depression Care
The Association Between Rural Residence and the Use, Type, and Quality of Depression Care John C. Fortney 1,2,3 Jeffrey S. Harman 4 Stanley Xu 5 Fran Dong 6 1. South Central Mental Illness Education and
More informationcare physicians (4 8). As a result, government agencies, accrediting organizations for example, the National Committee for Quality Assurance and
Aligning Incentives in the Treatment of Depression in Primary Care With Evidence-Based Practice Richard G. Frank, Ph.D. Haiden A. Huskamp, Ph.D. Harold Alan Pincus, M.D. Deficits in the quality of treatment
More informationA Retrospective Claims Analysis of Medication Adherence and. Persistence Among Patients Taking Antidepressants
A Retrospective Claims Analysis of Medication Adherence and Persistence Among Patients Taking Antidepressants for the Treatment of Major Depressive Disorder (MDD) Katelyn R. Keyloun A thesis submitted
More informationDepression intervention via referral, education, and collaborative treatment (Project DIRECT): a pilot study
Executive summary of completed research Depression intervention via referral, education, and collaborative treatment (Project DIRECT): a pilot study Principal Investigator Jane McCusker, MD DrPH Co-investigators
More informationQuality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care
Quality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationINSTRUCTION MANUAL Instructions for Patient Health Questionnaire (PHQ) and GAD-7 Measures
PHQ and GAD-7 Instructions P. 1/9 INSTRUCTION MANUAL Instructions for Patient Health Questionnaire (PHQ) and GAD-7 Measures TOPIC PAGES Background 1 Coding and Scoring 2, 4, 5 Versions 3 Use as Severity
More informationThe American healthcare system, particularly the managed
REPORTS Collaborative Care and Motivational Interviewing: Improving Depression Outcomes Through Patient Empowerment Interventions Bill Anderson, PharmD The American healthcare system, particularly the
More informationThe dramatic growth of managed. Use of Psychiatrists, Psychologists, and Master s-level Therapists in Managed Behavioral Health Care Carve-Out Plans
Use of Psychiatrists, Psychologists, and Master s-level Therapists in Managed Behavioral Health Care Carve-Out Plans Roland Sturm, Ph.D. Ruth Klap, Ph.D. Objective: Outpatient claims data from a managed
More informationUndertreatment of Panic Disorder in Primary Care: Role of Patient and Physician Characteristics
Undertreatment of Panic Disorder in Primary Care: Role of Patient and Physician Characteristics Peter Roy-Byrne, MD, Joan Russo, PhD, David C. Dugdale, MD, Daniel Lessler, MD, Deborah Cowley, MD, and Wayne
More informationinitiating antidepressant treatment
Follow-Up Visits by Provider Specialty for Patients With Major Depressive Disorder Initiating Antidepressant Treatment Shih-Yin Chen, Ph.D. Richard A. Hansen, Ph.D. Joel F. Farley, Ph.D. Bradley N. Gaynes,
More informationAntidepressant Medication Mgmt
August 2012 MHSPHP Background The Military Health System Population Health Portal (MHSPHP) methodology is based on 2012 Healthcare Effectiveness Data and Information Set (HEDIS ) criteria. These are a
More informationCare Team Training. Key Components of Collaborative Care. Collaborative Team Approach 4/21/2014 PCP. Core Program. New Roles. Psychiatric Consultant
Team Training Key Components of Collaborative Collaborative Team Approach Patient PCP Manager New Roles Core Program Psychiatric Consultant Behavioral Health Clinicians Additional Clinic Resources Substance,
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationORIGINAL INVESTIGATION. Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression
ORIGINAL INVESTIGATION Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression Patricia K. Corey-Lisle, PhD, RN-CSP; Rowena Nash, BA, BS; Paul Stang, PhD; Ralph Swindle, PhD
More informationCollaborative Care Management of Late-Life Depression in the Primary Care Setting JAMA. 2002;288:
ORIGINAL CONTRIBUTION Collaborative Care Management of Late-Life Depression in the Primary Care Setting A Randomized Controlled Trial Jürgen Unützer, MD, MPH Wayne Katon, MD Christopher M. Callahan, MD
More informationGUIDELINES ISSUED BY THE
THE PATIENT-PHYSICIAN RELATIONSHIP Discontinuation of Use and Switching of Antidepressants Influence of Patient-Physician Communication Scott A. Bull, PharmD X. Henry Hu, MD, MPH, PhD Enid M. Hunkeler,
More informationFollow-Up and Follow-Through of Depressed Patients in Primary Care: The Critical Missing Components of Quality Care
Follow-Up and Follow-Through of Depressed Patients in Primary Care: The Critical Missing Components of Quality Care Leif I. Solberg, MD, Michael A. Trangle, MD, and Arthur P. Wineman, MD Certainly we could
More informationAge of Depressed Patient Does Not Affect Clinical Outcome in Collaborative Care Management
CLINICAL FOCUS: ADHD, DEPRESSION, PAIN, AND NEUROLOGICAL DISORDERS Age of Depressed Patient Does Not Affect Clinical Outcome in Collaborative Care Management DOI: 10.3810/pgm.2011.09.2467 Kurt B. Angstman,
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationPhysician Knowledge, Financial Incentives and Treatment Decisions for Depression
The Journal of Mental Health Policy and Economics J. Mental Health Policy Econ. 1: 89 100 (1998) Physician Knowledge, Financial Incentives and Treatment Decisions for Depression Roland Sturm* and Kenneth
More informationORIGINAL ARTICLE. The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression
ORIGINAL ARTICLE The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression Catherine A. Melfi, PhD; Anita J. Chawla, PhD; Thomas W. Croghan, MD; Mark P. Hanna,
More informationSTAKEHOLDER BENEFIT FROM DEPRESSION DISEASE MANAGEMENT: DIFFERENCES BY RURALITY?
STAKEHOLDER BENEFIT FROM DEPRESSION DISEASE MANAGEMENT: DIFFERENCES BY RURALITY? Kathryn Rost, PhD Stanley Xu, PhD Fran Dong, MS L. Miriam Dickinson, PhD April 2008 Working Paper Western Interstate Commission
More informationDepression is a highly prevalent condition that results in
ORIGINAL ARTICLE Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression Julie M. Donohue, PhD,* Ernst R. Berndt, PhD, Meredith Rosenthal, PhD, Arnold M. Epstein, MD,
More informationANTIDEPRESSANT MEDICATION USE AMONG FIRST NATIONS PEOPLES RESIDING WITHIN BRITISH COLUMBIA
ANTIDEPRESSANT MEDICATION USE AMONG FIRST NATIONS PEOPLES RESIDING WITHIN BRITISH COLUMBIA Dennis Wardman, M.D. and Nadia Khan, M.D. Abstract: Very little is known about antidepressant medication use among
More informationEffective Treatment of Depression in Older African Americans: Overcoming Barriers
Effective Treatment of Depression in Older African Americans: Overcoming Barriers R U T H S H I M, M D, M P H A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F P S Y C H I A T R Y A N D B E
More informationMANAGERIAL. Frequency of Follow-up Care for Adult and Pediatric Patients During Initiation of Antidepressant Therapy
Frequency of Follow-up Care for Adult and Pediatric Patients During Initiation of Antidepressant Therapy Glen D. Stettin, MD; Jianying Yao, MS; Robert R. Verbrugge, PhD; and Ronald E. Aubert, PhD Objectives:
More informationRecent studies support the effectiveness of disease management
ORIGINAL ARTICLE How a Therapy-Based Quality Improvement Intervention for Depression Affected Life Events and Psychological Well-Being Over Time A 9-Year Longitudinal Analysis Cathy Donald Sherbourne,
More informationPsychiatry in a Collaborative System-Level and Practice-Level
Psychiatry in a Collaborative System-Level and Practice-Level Robin M. Reed, MD, MPH Presentation for the North Carolina Psychiatric Association October 2 nd 2015 Disclosures I have no relevant financial
More informationUniversity of Washington
Integrated Mental Health Care: closing the gap between what we know and what we do. Jürgen Unützer, MD, MPH, MA Professor & Vice-Chair Psychiatry and Behavioral Sciences University of Washington unutzer@uw.edu
More informationThe impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients
General Hospital Psychiatry 26 (2004) 199 209 The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients David A. Adler, M.D. a,b,c, *, Kathleen M. Bungay, Pharm.D.
More informationDepression in Chronic Physical Health Problems FULL GUIDELINE 1
O Connor 2005 U.S.A. Sertraline Placebo Study design data source Patients who were hospitalised for acute coronary syndromes and who met the APA s DSMIV criteria for major depressive disorder (MDD). :
More informationTaking Care: Child and Youth Mental Health TREATMENT OPTIONS
Taking Care: Child and Youth Mental Health TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS With appropriate treatment, more than 80% of people with depression get full relief from their symptoms
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More information2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an
Quality ID #370 (NQF 0710): Depression Remission at Twelve Months National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention, Treatment, and Management of Mental Health
More informationMeasurement-based Scales in Major Depressive Disorder:
This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka Pharmaceutical Development and Commercialization, Inc.
More informationSECOND-GENERATION ANTIDEPRESSANT USE IN TREATMENT FOR MAJOR DEPRESSIVE DISORDER-AN EXAMINATION OF GUIDELINE COMPONENTS AND HEALTHCARE UTILIZATION
SECOND-GENERATION ANTIDEPRESSANT USE IN TREATMENT FOR MAJOR DEPRESSIVE DISORDER-AN EXAMINATION OF GUIDELINE COMPONENTS AND HEALTHCARE UTILIZATION Shih-Yin Chen A dissertation submitted to the faculty of
More informationNonwhite populations have a. Racial-Ethnic Composition of Provider Practices and Disparities in Treatment of Depression and Anxiety,
Racial-Ethnic Composition of Provider Practices and Disparities in Treatment of Depression and Anxiety, 2003 2007 Isabel T. Lagomasino, M.D., M.P.H. Susan E. Stockdale, Ph.D. Jeanne Miranda, Ph.D. Objectives:
More informationDespite its prevalence in the managed. A Step Therapy Algorithm for the Treatment and Management of Chronic Depression REPORT
REPORT A Step Therapy Algorithm for the Treatment and Management of Chronic Depression Jeffrey D. Dunn, PharmD, MBA; and John G. Tierney, MD Abstract Depression is a chronic and progressive condition that,
More informationPsychiatric Consultant Role in Collaborative Care Sept 12, 2013
New York State Collaborative Care Initiative Psychiatric Consultant Role in Collaborative Care Sept 12, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationDepression: The Benefits of Early and Appropriate Treatment
REPORTS Depression: The Benefits of Early and Appropriate Treatment Aron Halfin, MD Abstract Depression has a profound impact on patient health, individual and family quality of life, activities of daily
More informationSupplementary figures and tables. Figure A: Study schematic
Supplementary figures and tables Figure A: Study schematic Figure B: Percent of patients with a normal (green), borderline (beige), abnormal (brown), or high (red) electrocardiogram 14-90 days after prescription
More informationDefinition. Synonyms 9/23/2010. Trials for which the hypothesis and study design are formulated based on information needed to make a decision
Scott Ramsey, MD, PhD Definition Trials for which the hypothesis and study design are formulated based on information needed to make a decision Synonyms Pragmatic clinical trials Practical clinical trials
More informationDepression: Assessment and Treatment For Older Adults
Tool on Depression: Assessment and Treatment For Older Adults Based on: National Guidelines for Seniors Mental Health: the Assessment and Treatment of Depression Available on line: www.ccsmh.ca www.nicenet.ca
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationQuality Improvement With Pay-for-Performance Incentives in Integrated Behavioral Health Care
Quality Improvement With Pay-for-Performance Incentives in Integrated Behavioral Health Care Jürgen Unützer, MD, MPH, MA, Ya-Fen Chan, PhD, Erin Hafer, MPH, Jessica Knaster, MPH, Anne Shields, RN, MPH,
More informationPharmacologic Treatment of Acute Major Depression and Dysthymia
POSITION PAPERS CLINICAL GUIDELINE, PART 1 Pharmacologic Treatment of Acute Major Depression and Dysthymia Vincenza Snow, MD; Steven Lascher, DVM, MPH; and Christel Mottur-Pilson, PhD, for the American
More informationAdequacy of antidepressant
Course of Antidepressant Treatment, Drug Type, and Prescriber s Specialty Kathleen A. Fairman, M.A. Wayne C. Drevets, M.D. Jerold J. Kreisman, M.D. Fred Teitelbaum, Ph.D. Objective: The study examined
More information$"% & '( ) " * +, !"##!""$ !*$-!+*" % $&
! """# # $"% & '( ')&# '( ) " * +, '( )(*!*$-!+*"!"##!""$ % $& &. / 011 12 ' 32 3 456 3. 3 0 11 32! 71 829:1 1' 3,3 12/ 2 31:181' 337)1 / 111 3 : 39.21)2 231 1 1 13' 223 333 23) 3;3 2 1 1' 11 3 31 333
More informationEffective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)
Protocol Title: Depression & Generalized Anxiety Disorder Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017) Group
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationCARE FOR DEPRESSION IN A CHANGING ENVIRONMENT
CARE FOR DEPRESSION IN A CHANGING ENVIRONMENT by Kenneth B. Wells and Roland Sturm Prologue: Psychologist Martin Seligman has referred to depression as "the common cold of mental illness." The incidence
More informationManaging Depression as a Chronic Condition. D. Green MD TOH/Bruyere Shared Care Program
Managing Depression as a Chronic Condition D. Green MD TOH/Bruyere Shared Care Program None Financial disclosure Objectives To review key concepts relevant to understanding the course of depression To
More informationDepression Assessment and Management. John Kern MD Clinical Professor University of Washington
Depression Assessment and Management John Kern MD Clinical Professor University of Washington Handouts Antidepressant Treatment Flowchart Managing antidepressant nonresponse handouts 2 Diagnosis PHQ-9
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationAntidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationMental disorders can be very. A Meta-Analysis of Labor Supply Effects of Interventions for Major Depressive Disorder
A Meta-Analysis of Labor Supply Effects of Interventions for Major Depressive Disorder Justin W. Timbie, B.A. Marcela Horvitz-Lennon, M.D., M.P.H. Richard G. Frank, Ph.D. Sharon-Lise T. Normand, Ph.D.
More informationOffice of Health Equity Advisory Committee Meeting
Office of Health Equity Advisory Committee Meeting Disparities in Mental Health Status and Care Sergio Aguilar-Gaxiola, MD, PhD Professor of Clinical Internal Medicine Director, Center for Reducing Health
More informationThe Patient Health Questionnaire-2
MEDICAL CARE Volume 41, Number 11, pp 1284 1292 2003 Lippincott Williams & Wilkins, Inc. The Patient Health Questionnaire-2 Validity of a Two-Item Depression Screener KURT KROENKE, MD,* ROBERT L. SPITZER,
More informationUniversity of Groningen
University of Groningen Are effects of depression management training for General Practitioners on patient outcomes mediated by improvements in the process of care? van Os, TWDP; van den Brink, Robertus;
More informationAntidepressant Prior Authorization Request
Antidepressant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationIntegrating Behavioral Health and Primary Care. Jürgen Unützer, MD, MPH, MA University of Washington November 13, 2013
Integrating Behavioral Health and Primary Care Jürgen Unützer, MD, MPH, MA University of Washington November 13, 2013 Jürgen Unützer, MD, MPH, MA Disclosures Employment: University of Washington Professor
More informationPATIENT HEALTH QUESTIONNAIRE (PHQ-9) NAME: DATE: Over the last 2 weeks, how often have you been bothered by any of the following problems? (use to ind
CONCISE REVIEW FOR CLINICIANS DEPRESSION MANAGEMENT IN PRIMARY CARE USING PHQ-9 A System-Based Approach to Depression Management in Primary Care Using the Patient Health Questionnaire-9 RAMONA S. DEJESUS,
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationIdentifying Adult Mental Disorders with Existing Data Sources
Identifying Adult Mental Disorders with Existing Data Sources Mark Olfson, M.D., M.P.H. New York State Psychiatric Institute Columbia University New York, New York Everything that can be counted does not
More informationRetrospective Analysis of the Health-Care Costs of Bupropion Sustained Release in Comparison with Other Antidepressants
Volume 4 Number 5 2001 VALUE IN HEALTH Retrospective Analysis of the Health-Care Costs of Bupropion Sustained Release in Comparison with Other Antidepressants Amy W. Poret, SM 1 Cheryl Neslusan, PhD, 2
More informationTelephone Cognitive Behavioral Therapy for Rural Latinos: A Randomized Pilot Study
Telephone Cognitive Behavioral Therapy for Rural Latinos: A Randomized Pilot Study Gino Aisenberg, PhD UW School of Social Work Megan Dwight Johnson, MD MPH RAND Corporation Daniela Golinelli,, PhD RAND
More informationDisclosures. Objectives. Chronic Pain: A critical problem among Veterans 10/8/2015
Interventions to Improve the Management of Chronic Back Pain The Primary Care Perspective Matthew J. Bair, MD, MS Center for Health Information and Communication, Regenstrief Institute, Inc, and Indiana
More informationTREATMENT OF DEPRESSION IN AFRICAN AMERICAN PRIMARY CARE PATIENTS
TREATMENT OF DEPRESSION IN AFRICAN AMERICAN PRIMARY CARE PATIENTS Charlotte Brown, Ph.D., Department of Psychiatry, Health and Behavior Studies Program, University of Pittsburgh School of Medicine Deena
More informationMental Health Nursing: Mood Disorders. By Mary B. Knutson, RN, MS, FCP
Mental Health Nursing: Mood Disorders By Mary B. Knutson, RN, MS, FCP A Definition of Mood Prolonged emotional state that influences the person s whole personality and life functioning Adaptive Functions
More informationThe Value of Providing Collaborative Care Models For Treating Employees with Depression
The Value of Providing Collaborative Care Models For Treating Employees with Depression Summary Depression is one of the costliest health issues for employers because of its high prevalence and co-morbidity
More informationAntidepressant medications are. Antidepressant Switching Among Adherent Patients Treated for Depression
Antidepressant Switching Among Adherent Patients Treated for Depression Steven C. Marcus, Ph.D. Mariam Hassan, Ph.D. Mark Olfson, M.D., M.P.H. Objective: This study examined the pharmacologic, clinical,
More information